DARA Biosciences (FRA:PJUF) Days Payable : 287.39 (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is DARA Biosciences Days Payable?

DARA Biosciences's average Accounts Payable for the three months ended in Sep. 2015 was €0.67 Mil. DARA Biosciences's Cost of Goods Sold for the three months ended in Sep. 2015 was €0.21 Mil. Hence, DARA Biosciences's Days Payable for the three months ended in Sep. 2015 was 287.39.

The historical rank and industry rank for DARA Biosciences's Days Payable or its related term are showing as below:

FRA:PJUF' s Days Payable Range Over the Past 10 Years
Min: 395.12 Med: 1033.33 Max: 21033.13
Current: 395.12

During the past 13 years, DARA Biosciences's highest Days Payable was 21033.13. The lowest was 395.12. And the median was 1033.33.

FRA:PJUF's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 148.01 vs FRA:PJUF: 395.12

DARA Biosciences's Days Payable declined from Sep. 2014 (670.87) to Sep. 2015 (287.39). It may suggest that DARA Biosciences accelerated paying its suppliers.

DARA Biosciences Days Payable Historical Data

The historical data trend for DARA Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DARA Biosciences Days Payable Chart

DARA Biosciences Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Days Payable

Get a 7-Day Free Trial

15,624.03

1,718.92

428.37

DARA Biosciences Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Days Payable	Get a 7-Day Free Trial															670.87	373.80	302.27	207.96	287.39

Competitive Comparison of DARA Biosciences's Days Payable

For the Biotechnology subindustry, DARA Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DARA Biosciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DARA Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where DARA Biosciences's Days Payable falls into.

DARA Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

DARA Biosciences's Days Payable for the fiscal year that ended in Dec. 2014 is calculated as

	Days Payable (A: Dec. 2014 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2013 )	+	Accounts Payable (A: Dec. 2014 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2014 )	*	Days in Period
=	( (0.453	+	0.392)	/	2 )	/	0.36	*	365
=	0.4225					/	0.36	*	365
=	428.37

DARA Biosciences's Days Payable for the quarter that ended in Sep. 2015 is calculated as:

	Days Payable (Q: Sep. 2015 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2015 )	+	Accounts Payable (Q: Sep. 2015 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2015 )	*	Days in Period
=	( (0.553	+	0.795)	/	2 )	/	0.214	*	365 / 4
=	0.674					/	0.214	*	365 / 4
=	287.39

DARA Biosciences Days Payable Related Terms

Thank you for viewing the detailed overview of DARA Biosciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

DARA Biosciences (FRA:PJUF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (FRA:PJUF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.darabio.com

DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.

DARA Biosciences (FRA:PJUF) Headlines

No Headlines